Manisha Chandalia, MD
Endocrinology, Diabetes & Metabolism · Baytown, TXNPI 1750347217
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $323,679 of the $385,885 with a category attached, or 83.9%. 52 manufacturers reported payments, led by Lilly USA, LLC at 31.3% of the total. Reporting peaked in 2019 at $128,120 and has fallen 83.4% since, to $21,266 in 2025. Among endocrinology, diabetes & metabolism clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 872 payments — averaging $442.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$121K
- Boehringer Ingelheim$115K
- AstraZeneca$75K
- Novo Nordisk$51K
- Amgen$12K
- Regeneron$4K
- plus $9K from 46 others
Across 1 payment — averaging $5150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$5K
What the payments were for
- Consulting fees$32,0778%
- Speaking & faculty fees$323,67984%
- Travel & lodging$13,2183%
- Food & beverage$16,5664%
- Education$2270%
- Gifts$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$385,885 in reported general payments places this provider in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 622 | $824,690 |
| JardianceEmpagliflozin | 698 | $659,347 |
| MounjaroTirzepatide | 433 | $532,380 |
| FarxigaDapagliflozin Propanediol | 391 | $371,477 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 210 | $234,529 |
| TrulicityDulaglutide | 163 | $233,402 |
| TymlosAbaloparatide | 31 | $110,628 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 130 | $108,681 |
| Tresiba Flextouch U-100Insulin Degludec | 156 | $104,125 |
| Xigduo XrDapaglifloz Propaned/Metformin | 71 | $74,015 |
| TradjentaLinagliptin | 42 | $56,929 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $37,669 |
| JanuviaSitagliptin Phosphate | 29 | $36,407 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 25 | $33,075 |
| Tresiba Flextouch U-200Insulin Degludec | 34 | $32,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $50,784 | $858,584650 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $114,550 | $824,958870 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $120,938 | $771,932623 claims |
| AstraZenecaFarxiga | $74,724 | $371,477391 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $277 | $239,877228 claims |
| Radius Health, Inc.Tymlos | $377 | $110,62831 claims |
| MerckJanuvia, Janumet Xr | $2,879 | $68,85253 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $52 | $7,008598 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Baytown
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
- Mitchell SorsbyPlano$945K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.